Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 5/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258964 | 0.91 | PTGIR (0.43) | PTGIR | |
| SCHEMBL21258713 | 0.90 | CKS1B (0.35) | HTR1AOPRM1 | |
| SCHEMBL23656082 | 0.90 | HSD17B10 (0.36) | OPRM1PTGIR | |
| SCHEMBL21258925 | 0.90 | PTGIR (0.35) | PTGIR | |
| SCHEMBL21258656 | 0.90 | PTGIR (0.42) | HTR1APTGIR | |
| SCHEMBL21258940 | 0.89 | PTGIR (0.35) | PTGIR | |
| SCHEMBL21258959 | 0.89 | PTGIR (0.38) | HTR1AOPRM1PTGIRDRD4 | |
| SCHEMBL24863729 | 0.88 | HTR1A (0.32) | HTR1A | |
| SCHEMBL21258828 | 0.85 | PTGIR (0.37) | PTGIR | |
| SCHEMBL21258676 | 0.84 | PTGIR (0.38) | PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | CHINESE PLA GENERAL HOSPITAL (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | HTR1A 295/4885OPRM1 341/4885PTGIR 1/4885 |
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | PTGIR, CYP11B2, PDE8A | HTR1A 406/4885OPRM1 289/4885PTGIR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.